Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, Christina Chambers, Joy Derwenskus, Virginia Devonshire, Kerstin Hellwig, George J. Hutton, Pamela McCombe, Marie Moore, David Rog, Jean-Raphael Schneider, Renata Simm, Lívia Sousa, Stephen G. Vincent, Luke Chung, Nadia Daizadeh, Colin Mitchell, D. A. S. Compston